Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 3121 - 3128 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7689 | human Insulin expressed in yeast |
|
Endogenous insulin receptor agonist (Ki = 4.85 nM). Decreases plasma glucose levels, proteolysis, lipolysis and gluconeogenesis and increases glycogen and fatty acid synthesis in vivo.
|
|
| BCC7690 | [D-Trp34]-Neuropeptide Y |
|
Potent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and Y4 receptors respectively. Induces hyperphagia, body weight gain, adiposity, hypercholesterolemia, hyperinsulinemia and hyperleptinemia in vivo. Orally active.
|
|
| BCC7691 | Astemizole |
|
Orally active, potent histamine H1 antagonist (IC50 = 4 nM) that displays 20-fold, > 250-fold and > 250-fold selectivity over 5-HT, dopamine and muscarinic acetylcholine receptors respectively. Exhibits antimalarial activity in multidrug resistant strains in vitro (IC50 = 227 - 734 nM). Also potent KV11.1 (hERG) channel blocker (IC50 = 0.9 nM) that displays cardiotoxicity in vivo.
|
|
| BCC7692 | UCPH 101 |
|
Selective non-substrate inhibitor of EAAT1 (IC<sub>50</sub> values are 660, >300000 and >300000 nM for EAAT1, EAAT2 and EAAT3 respectively). Also demonstrates no significant inhibition at EAAT4 or EAAT5 in a patch-clamp electrophysiology assay (at final concentration up to 10 <span class='symbol'>μ</span>M).
|
|
| BCC7693 | Cyclosomatostatin |
|
Non-selective somatostatin (sst) receptor antagonist. Blocks the effects of sst on airway <span class='symbol'>β</span>-adrenergic function, CRF-induced suppression of gastric empyting, modulation of ACh release and growth hormone, insulin and glucagon release. Reported to act as an sst receptor agonist in human neuroblastoma cell line SH-SY5Y.
|
|
| BCC7694 | RGDS peptide |
|
Integrin binding sequence that inhibits integrin receptor function. Decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. Promotes cell attachment and abrogates apoptosis via the mitochondrial pathway in osteoblasts in vitro.
|
|
| BCC7695 | ML 10302 hydrochloride |
|
Potent 5-HT<sub>4</sub> partial agonist (EC<sub>50</sub> = 4 nM) that displays > 680-fold selectivity over 5-HT<sub>3</sub> receptors (K<sub>i</sub> values are 1.07 and 730 nM respectively). Increases sAPP<span class='symbol'>α</span> levels in the cortex in an animal model of Alzheimer's disease and exhibits progastrokinetic effects <em>in vivo</em>.
|
|
| BCC7696 | LG 101506 |
|
Selective RXR modulator (K<sub>i</sub> values are 3, 9 and 11 for RXR<span class='symbol'>α</span>, RXR<span class='symbol'>β</span> and RXR<span class='symbol'>γ</span> respectively). Displays poor binding affinity for RAR isoforms (K<sub>i</sub> values are 2746, 3516 and >10,000 nM for RAR<span class='symbol'>α</span>, RAR<span class='symbol'>β</span> and RAR<span class='symbol'>γ</span> respectively). Binding to RXR results in selective activation of RXR:PPAR<span class='symbol'>γ</span>, RXR:PPAR<span class='symbol'>α</span> and RXR:PPAR<span class='symbol'>δ</span> heterodimers.
|
|